Targeted mitochondrial delivery of antisense RNA-containing nanoparticles by a MITO-Porter for safe and efficient mitochondrial gene silencing.


Journal

Mitochondrion
ISSN: 1872-8278
Titre abrégé: Mitochondrion
Pays: Netherlands
ID NLM: 100968751

Informations de publication

Date de publication:
11 2019
Historique:
received: 29 11 2018
revised: 09 08 2019
accepted: 19 08 2019
pubmed: 1 9 2019
medline: 7 5 2020
entrez: 1 9 2019
Statut: ppublish

Résumé

Mitochondrial gene therapy will be needed to treat mitochondrial diseases. We previously demonstrated mitochondrial gene silencing by the mitochondrial delivery of antisense RNA oligonucleotide (ASO) targeting mtDNA-encoded mRNA using a MITO-Porter, a liposomal nano carrier system designed for mitochondrial delivery. Here, we report on the efficient packaging of ASO in the MITO-Porter via a nanoparticle packaging method, which showed a 10-fold higher packaging efficiency than the conventional method. The constructed carrier showed a decrease in the target mRNA levels and ATP production. These results indicate that such a MITO-Porter has potential for use in therapies designed to regulate mitochondrial function.

Identifiants

pubmed: 31472283
pii: S1567-7249(18)30286-1
doi: 10.1016/j.mito.2019.08.004
pii:
doi:

Substances chimiques

RNA, Antisense 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

178-188

Informations de copyright

Copyright © 2019 Elsevier B.V. and Mitochondria Research Society. All rights reserved.

Auteurs

Eriko Kawamura (E)

Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Mitsue Hibino (M)

Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Hideyoshi Harashima (H)

Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Yuma Yamada (Y)

Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan. Electronic address: u-ma@pharm.hokudai.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH